PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy

SIMPLE SUMMARY: Immune checkpoint inhibitors (ICI) are now part of the therapeutical arsenal for cancers at several sites and in several settings. PD-L1 expression is assessed to predict treatment response. We used immunohistochemistry (E1L3N clone) to assess PD-L1 expression on tumor and immune cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Grandal, Beatriz, Mangiardi-Veltin, Manon, Laas, Enora, Laé, Marick, Meseure, Didier, Bataillon, Guillaume, El-Alam, Elsy, Darrigues, Lauren, Dumas, Elise, Daoud, Eric, Vincent-Salomon, Anne, Talagrand, Laure-Sophie, Pierga, Jean-Yves, Reyal, Fabien, Hamy, Anne-Sophie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916886/
https://www.ncbi.nlm.nih.gov/pubmed/33670162
http://dx.doi.org/10.3390/cancers13040746

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916886/
https://www.ncbi.nlm.nih.gov/pubmed/33670162
http://dx.doi.org/10.3390/cancers13040746

Ejemplares similares